A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma

Ong, 1996, Chemotherapy in malignant pleural mesothelioma: a review, J. Clin. Oncol., 14, 1007, 10.1200/JCO.1996.14.3.1007 Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J. Clin. Oncol., 21, 2636, 10.1200/JCO.2003.11.136 Zalcman, 2016, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, 387, 1405, 10.1016/S0140-6736(15)01238-6 Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J. Clin. Oncol., 26, 1698, 10.1200/JCO.2006.09.9887 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ Br. Med. J. (Clin. Res. Ed.), 327, 557, 10.1136/bmj.327.7414.557 Begg, 1994, Operating characteristics of a rank correlation test for publication bias author ( s ): Colin B. Begg and Madhuchhanda Mazumdar published by : international Biometric society stable, Biometrics, 50, 1088, 10.2307/2533446 Stuck, 1998, Bias in meta-analysis detected by a simple, graphical, Br. Med. J., 316, 10.1136/bmj.316.7129.469 Suurmond, 2017, Introduction, Comparison, and Validation of Meta-Essentials : a free and simple tool for meta-analysis, Res. Synth. Meth., 10.1002/jrsm.1260 Zucali, 2014, Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma, Lung Canc., 84, 265, 10.1016/j.lungcan.2013.11.011 Zucali, 2012, Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey, Lung Canc., 75, 360, 10.1016/j.lungcan.2011.08.011 Zucali, 2008, Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma, Cancer, 112, 1555, 10.1002/cncr.23337 Zauderer, 2014, Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma, Lung Canc., 84, 271, 10.1016/j.lungcan.2014.03.006 Toyokawa, 2014, Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy, Int. J. Clin. Oncol., 19, 601, 10.1007/s10147-013-0619-5 Xanthopoulos, 2008, Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study, J. Occup. Med. Toxicol., 3, 34, 10.1186/1745-6673-3-34 Wheatley-Price, 2016, A phase II study of PF-03446962 in patients with advanced malignant pleural mesothelioma. CCTG trial IND.207, J. Thorac. Oncol., 11, 2018, 10.1016/j.jtho.2016.06.024 Calabrò, 2013, Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol., 14, 1104, 10.1016/S1470-2045(13)70381-4 Steer, 2010, Life after first-line chemotherapy in malignant pleural mesothelioma: a north-east england experience, Clin. Oncol., 22, 231, 10.1016/j.clon.2010.01.009 Stebbing, 2009, The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma, Lung Canc., 63, 94, 10.1016/j.lungcan.2008.04.001 Tourkantonis, 2011, Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma, Am. J. Clin. Oncol., 34, 38, 10.1097/COC.0b013e3181cae90e Reck, 2010, Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany, Respir. Med., 104, 142, 10.1016/j.rmed.2009.07.019 Raynaud, 2015, Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study), BMC Canc., 15, 857, 10.1186/s12885-015-1881-x Santoro, 2008, Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program, J. Thorac. Oncol., 3, 756, 10.1097/JTO.0b013e31817c73d6 Sørensen, 2007, Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment, J. Thorac. Oncol., 2, 147, 10.1097/JTO.0b013e31802f3813 Papa, 2013, Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-Containing chemotherapy, J. Thorac. Oncol., 8, 783, 10.1097/JTO.0b013e31828c2b26 Pasello, 2011, Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience, Lung Canc., 73, 351, 10.1016/j.lungcan.2011.01.005 Ramalingam, 2009, Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma, J. Thorac. Oncol., 4, 97, 10.1097/JTO.0b013e318191520c Porta, 2005, Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients, Lung Canc., 48, 429, 10.1016/j.lungcan.2004.11.015 Mutlu, 2014, Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study, Med. Oncol., 31, 10.1007/s12032-014-0074-9 Nowak, 2012, A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma, J. Thorac. Oncol., 7, 1449, 10.1097/JTO.0b013e31825f22ee Manegold, 2005, Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma, Ann. Oncol., 16, 923, 10.1093/annonc/mdi187 Janne, 2006, Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program, J. Thorac. Oncol., 1, 506, 10.1097/01243894-200607000-00002 Jackman, 2008, Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma, Cancer, 113, 808, 10.1002/cncr.23617 Nowak, 2013, A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma, Lung Canc., 81, 422, 10.1016/j.lungcan.2013.05.006 Krug, 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol., 16, 447, 10.1016/S1470-2045(15)70056-2 Kostron, 2016, Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma, Eur J Cardio-thoracic Surg, 49, 1516, 10.1093/ejcts/ezv398 Laurie, 2011, Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC clinical trials group, J. Thorac. Oncol., 6, 1950, 10.1097/JTO.0b013e3182333df5 Giaccone, 2002, Phase II trial of ZD0473 as second-line therapy in mesothelioma, Eur. J. Canc., 38, S19, 10.1016/S0959-8049(02)80018-1 Maio, 2017, Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial, Lancet Oncol., 1261, 10.1016/S1470-2045(17)30446-1 Laurie, 2017, A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group, Lung Canc., 104, 65, 10.1016/j.lungcan.2016.12.004 Garland, 2011, Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509, J. Thorac. Oncol., 6, 1938, 10.1097/JTO.0b013e318229586e Gunduz, 2014, Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma, Asian Pac. J. Cancer Prev. APJCP, 15, 8843, 10.7314/APJCP.2014.15.20.8843 Gregorc, 2010, Phase II study of asparagine-glycine-arginine-human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma, J. Clin. Oncol., 28, 2604, 10.1200/JCO.2009.27.3649 Dubey, 2010, A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307, J. Thorac. Oncol., 5, 1655, 10.1097/JTO.0b013e3181ec18db Dudek, 2012, Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a Brief report, J. Thorac. Oncol., 7, 755, 10.1097/JTO.0b013e318248242c Fennell, 2012, Phase II clinical trial of first or second-line treatment with Bortezomib in patients with malignant pleural mesothelioma, J. Thorac. Oncol., 7, 1466, 10.1097/JTO.0b013e318260dfb9 Fennell, 2007, Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma, Cancer, 109, 93, 10.1002/cncr.22366 Campbell, 2012, Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium, Lung Canc., 78, 76, 10.1016/j.lungcan.2012.06.011 Dogan, 2014, The clinicopathological characteristics with long-term outcomes in malignant mesothelioma, Med. Oncol., 31, 232, 10.1007/s12032-014-0232-0 Ceresoli, 2011, Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma, Lung Canc., 72, 73, 10.1016/j.lungcan.2010.12.004 Calabrò, 2015, Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study, Lancet Respir Med, 3, 301, 10.1016/S2213-2600(15)00092-2 Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol., 18, 623, 10.1016/S1470-2045(17)30169-9 Bearz, 2012, Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience, BMC Res. Notes, 5, 482, 10.1186/1756-0500-5-482 Beebe-Dimmer, 2016, Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)–medicare investigation of treatment patterns and overall survival, Clin. Epidemiol., 8, 743, 10.2147/CLEP.S105396 Özyılkan, 2014, Malignant pleural mesothelioma: a single-center experience in Turkey, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res., 20, 825 Scherpereel, 2011, Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study, Eur. Respir. J., 37, 129, 10.1183/09031936.00037310 Novello, 2016, The third Italian Consensus Conference for malignant pleural mesothelioma: state of the art and recommendations, Crit. Rev. Oncol. Hematol., 104, 9, 10.1016/j.critrevonc.2016.05.004 Baas, 2015, Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 26, v31, 10.1093/annonc/mdv199 Scherpereel, 2018, Novel therapies for malignant pleural mesothelioma, Lancet Oncol., 19, e161, 10.1016/S1470-2045(18)30100-1 Patil, 2018, Molecular and histopathological Characterization of the tumor immune Microenvironment in advanced stage of malignant pleural mesothelioma, J. Thorac. Oncol., 13, 124, 10.1016/j.jtho.2017.09.1968